Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Correction Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase Ⅲ Study ).

NCT00433693 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT00433693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00433693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Correction Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase Ⅲ Study ).
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2007
Completion date
October 31, 2008
Enrollment
50 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis patients